KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress
KalVista Pharmaceuticals, Inc. (KALV)
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kalvista.com
Company Research
Source: Business Wire
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025.Details are as follows:Thursday, October 2 at 4:00–5:15 pm CEST:Time to End of Progression of Hereditary Angioedema Attacks Treated with Sebetralstat: Markus Magerl, Inmaculada Martinez-Saguer, William R. Lumry, John Anderson, Jonathan A. Bernstein, Mauro Cancian, Danny M. Cohn, Henriette Farkas, Henry Li, James Hao, Michael Smith, Paolo Bajcic, Paul Audhya, Petra Staubach, Emel Aygören-Pürsün.Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks in European Participants: Interim Analysis from KONFIDENT-S: Inmaculada Martinez-Saguer, Petra Staubach, Teresa Caballero, Mar Guilarte, Ramon Lleonart Bellfill, James Hao, Michael Smith, Paul Audhya, Markus Magerl, Emel Aygören-Pürsün.Effectiveness of Sebe
Show less
Read more
Impact Snapshot
Event Time:
KALV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KALV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KALV alerts
High impacting KalVista Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
KALV
News
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.MarketBeat
- KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]Yahoo! Finance
- KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
KALV
Earnings
- 11/10/25 - Beat
KALV
Sec Filings
- 12/4/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- KALV's page on the SEC website